STANDARD BIOTOOLS INC. 8K

Standard BioTools is selling its Mass Cytometry business to Multiplex Bio, received $30 million from Illumina to buy out SomaLogic-related contingent payments, and obtained HSR early termination to advance its pending merger with Treeline Biosciences.

Standard BioTools Inc. (NASDAQ: LAB) announced multiple transactions related to its pending merger with Treeline Biosciences, including an agreement to sell its Mass Cytometry business (CyTOF and Hyperion product lines) to newly formed Multiplex Bio, led by Michael Johnson, PhD, Tom Villani, PhD, and Charles Coffman, in a deal valued at up to $10 million plus a working capital loan of up to $10 million; receipt of approximately $30 million from Illumina, Inc. in a negotiated buyout of the 2026 earnout and all future royalty obligations from Illumina’s prior acquisition of Standard BioTools’ SomaLogic business, which will increase Standard BioTools’ pro forma net cash considered in the Treeline merger exchange ratio; and early termination by the U.S. Federal Trade Commission of the Hart‑Scott‑Rodino waiting period for the Treeline transaction, with both the Mass Cytometry sale and the Treeline merger expected to close by the end of 2026 subject to stockholder approval and customary conditions.

Filing Facts

CIK

1162194

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-029841

Alert Tier

8